COP vs KPTI · P/E 19, rev $34.92B vs rev $68.5M
ConocoPhillips (COP) versus Karyopharm Therapeutics Inc (KPTI) — a side-by-side from cached financials, not a winner call.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
Latest reported COP revenue for 2026-06-30 was $34.92B. Net income was $6.11B. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
COP currently screens at market cap $135.49B and trailing P/E 18.8. KPTI currently screens at market cap $205.6M.
Not investment advice. Open the COP and KPTI stock pages for the full models.
Not investment advice.